Company:  HYPERION THERAPEUTICS INC (HPTX)
Form Type:  8-K
Filing Date:  5/16/2013 
CIK:  0001386858 
Address:  2000 SIERRA POINT PARKWAY
SUITE 400
 
City, State, Zip:  BRISBANE, California 94005 
Telephone:  650-745-7802 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$25.53  
Change: 
-0.08 (-0.31%)  
Trade Time: 
Apr 24  
Market Cap: 
$517.34M
Description of Business
We are a commercial biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Our products, RAVICTI� (glycerol phenylbutyrate) Oral liquid, BUPHENYL� and AMMONAPS� (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. Ammonia is produced in the intestine after a person eats protein and is normally detoxified in the liver by conversion to urea. Elevated levels of ammonia are potentially toxic and can lead to severe medical complications which may include death. We have developed RAVICTI, which we launched during the first quarter of 2013, to treat most urea cycle disorders (�UCD�) including 7 of the 8 most prevalent UCD subtypes, and are developing glycerol phenylbutyrate (�GPB�), the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy (�HE�). UCD and HE are diseases in which blood ammonia is elevated.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01. Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 99.1
BROKERAGE PARTNERS